HOME **ABOUT** CONTACT **AVAILABLE ISSUES** SURSCRIRE MEDIA & ADS CONFERENCE CALENDAR





FEATURES

SPOTLIGHTS NEWS CRUNCH COLUMNS EYE ON CHINA INSIDE INDUSTRY BIOBOARD

EVENTS

LATEST UPDATES

1, November 2017 – Paediatric Illnesses » Breakthrough new rice variety announced in Northern China

» Ebola vaccine







PR NEWSWIRE

PR Newswire

Cedrus Investments' Executive Director Olivia Lam Was Invited to Present at the Australia Biotech Invest in MelBourne on 24th October

HONG KONG, Nov. 7, 2017 /PRNewswire/ -- Ms. Olivia Lam, Executive Director at Cedrus Investments ("Cedrus"), was one of the three keynote speakers at the "Australia Biotech Invest" $\ \, \text{held in Melbourne on 24}{}^{th} \,\, \text{October 2017}. \, \\ \text{This annual event organized by } \, \textbf{AusBiotech}, \, \text{an Australian life}$

sciences organization, attracted over 300 company executives in the industry and investors around the world attending this year. The Biotech Invest series, which also includes an annual investment conference in Hong Kong, has recently been expanded to Singapore and Shanghai in response to the rapidly-growing appetite for life sciences investments in Asia and the Greater China region. Since its inaugural conference in Hong Kong in 2013, Cedrus has been working closely with AusBiotech to foster investments in the life sciences industry across borders.



Cedrus Investments

Ms. Lam's presentation was focused on the opportunities and challenges encountered by Australian life sciences firms in raising capital, and forming partnerships and joint ventures with their counterparts or investors in the Greater China region. She also spoke about the usual structures of cross-border life sciences transactions and their respective advantages and disadvantages.

In recent years, Cedrus has been actively engaged in assisting life science companies from Australia and Europe to gain access to the Chinese market through private placements, identifying potential strategic business partners and investors, structuring and negotiating cross-border collaborations as well as setting up joint ventures.

Cedrus' Chairman, Mr. Rani Jarkas said, "We have seen growing interest from Chinese enterprises and investors to acquire life sciences technologies and products overseas, and the increased desire of Australian life science companies to build a presence in China, the second-largest biopharma market in the world. Through facilitating various deals, we have accumulated a lot of expertise and valuable experience in cross-border transactions and collaborations. We are happy to share them with investors and company executives, helping them achieve their strategic goals.'

About Cedrus Investments

Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

Media Enquiry:

Cedrus Investments Ltd. Amy Sin +852-3519-2828

information@cedrusinvestments.com

Logo - http://photos.prnasia.com/prnh/20150930/8521506461LOGO

SOURCE Cedrus Investments

NEWS CRUNCH

news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'

news Novogen becomes Kazia Therapeutics

news Transforming healthcare through innovation: addressing unmet healthcare needs in Asia Pacific

PR NEWSWIRE

LKK Health Products Group Consecutively Honored with "Partner Employer Award"

HONG KONG, 4 hours ago

Tekni-Plex announces new general manager for China operations

WAYNE, Pennsylvania, Tue, Nov 21 2017 9:00 PM

B. Braun Obtains Preliminary Injunction Against Poly Medicure (Polymed) for Misleading Advertising MELSUNGEN, Germany, Tue, Nov 21 2017 7:24 PM

NeuroVive Pharmaceutical AB Interim Report January - September 2017 STOCKHOLM, Tue, Nov 21 2017 3:56 PM

More news

EDITORS' CHOICE

Lady Ganga: Nilza'S Story

COLUMNS